Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
PTC Therapeutics
PTCT
PTC Therapeutics
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 16 Analysts
Published
04 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$103.38
52.2% undervalued
intrinsic discount
21 Aug
US$49.46
1Y
40.0%
7D
-0.3%
Loading
1Y
40.0%
7D
-0.3%
Author's Valuation
US$103.4
52.2% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$103.4
52.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-642m
2b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.4b
Earnings US$143.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-6.65%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.66%
Calculation
US$143.35m
Earnings '28
x
77.35x
PE Ratio '28
=
US$11.09b
Market Cap '28
US$11.09b
Market Cap '28
/
86.80m
No. shares '28
=
US$127.74
Share Price '28
US$127.74
Share Price '28
Discounted to 2025 @ 7.64% p.a.
=
US$102.42
Fair Value '25